Search

Search Constraints

You searched for: Author/Creator Weinstein, Arthur

Search Results

2. 237 Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus. (April 2019)

3. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE. Issue 1 (19th September 2019)

4. Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Issue 1 (1st October 2014)

5. THU0071 THE COMBINATION OF RHEUMATOID FACTORS WITH ANTIBODY SYSTEMS TARGETING CITRULLINATED, CARBAMYLATED AND PEPTIDYL ARGININE DEIMINASE AUTOANTIGENS DISTINGUISHES RHEUMATOID ARTHRITIS. (June 2019)

6. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Issue 7 (5th June 2019)

7. Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP). Issue 11 (12th October 2020)

8. Cell-bound complement activation products associate with lupus severity in SLE. Issue 1 (5th May 2020)

9. Cell-bound complement activation products associate with lupus severity in SLE. Issue 1 (5th May 2020)

10. Cell-bound complement activation products associate with lupus severity in SLE. Issue 1 (5th May 2020)